They reviewed patients enrolled in trials between 2007 and 2017 and found that the presence of segmental chromosomal abberations such as the loss or gain of a portion of the chromosomal arm can have a negative impact on patient outcomes.
He shared a recently updated paper from the Children's Oncology Group showing that the neuroblastoma tree is constantly changing as we're adding new information.
Update Course Rewind: Staging and Management of Neuroblastoma 2022
▶Ep 12 · 0:24
guidelineThe Children's Oncology Group neuroblastoma classification tree is constantly changing as new information is added↗
▶Ep 12 · 0:24
guidelineBased on the 2021 COG classification, the presented tumor would be classified as higher risk↗
▶Ep 12 · 0:24
epidemiologicalCOG reviewed patients enrolled in trials between 2007 and 2017↗
▶Ep 12 · 0:24
clinicalThe presence of segmental chromosomal aberrations such as loss or gain of a portion of the chromosomal arm can have a negative impact on patient outcomes↗
▶Ep 12 · 0:24
guidelineThe updated schema classifies tumors as high risk when there is no MYCN amplification but segmental chromosomal abnormalities are present↗
▶Ep 12 · 0:24
quoteHe shared a recently updated paper from the Children's Oncology Group showing that the neuroblastoma tree is constantly changing as we're adding new information.↗
▶Ep 12 · 0:42
quoteThey reviewed patients enrolled in trials between 2007 and 2017 and found that the presence of segmental chromosomal abberations such as the loss or gain of a portion of the chromosomal arm can have a negative impact on patient outcomes.↗
